Target intelligence / Profile preview

Diamorphine

Molecular classification
Other (semi-synthetic opioid, not a receptor, enzyme, or biological target)
01

Overview

Diamorphine (heroin) is a semi-synthetic opioid, chemically known as diacetylmorphine, first synthesized in 1874 by acetylating morphine derived from opium poppy latex. Heroin is a prodrug; after administration (by injection, inhalation, or insufflation), it rapidly crosses the blood–brain barrier and is deacetylated to 6-monoacetylmorphine and then to morphine, which binds to μ-opioid receptors to produce analgesic and euphoric effects. Heroin itself is not pharmacologically very active at opioid receptors, but its metabolites, primarily morphine, are. It is highly addictive, with significant risks including respiratory depression, coma, and death. While heroin (diamorphine) may be used in some countries as a prescription analgesic for severe pain, it is most widely known and regulated as a substance of abuse[1][2][3][4][7][9]. The pharmacological target for heroin's effects is the μ-opioid receptor (also called mu-opioid receptor or MOP receptor), which is a G protein-coupled receptor. However, heroin is not the receptor/target; rather, it acts as a ligand (drug) for that target once metabolized to morphine[2][7]. Interacting drugs for heroin (as a substance) include naloxone and naltrexone (opioid receptor antagonists used to counteract overdose), but these interact with opioid receptors, not with heroin as a molecular target[4][7].

Other names
Heroindiacetylmorphinediamorphine3,6-diacetylmorphine
02

Disease associations

Other (substance of abuse and regulated narcotic; not a therapeutic target)
03

Safety considerations

High risk of addictionoverdose/depression of respirationdeathdependencyinfectious disease transmission (injection)withdrawal
04

Biomarkers

6-monoacetylmorphinemorphine

Beyond the preview

Go deeper on Diamorphine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Diamorphine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call